Strides Pharma Secures NCLT Approval for OneSource, India's First Specialty Pharma CDMO
Advertisement
Mumbai: Strides Pharma Science Limited, on Tuesday, announced that the National Company Law Tribunal (NCLT), Mumbai Bench, has approved its Scheme of Arrangement, paving the way for the creation of OneSource, India’s first specialty pharmaceutical contract development and manufacturing organization (CDMO).
OneSource will unify the specialized businesses of Strides, Steriscience Specialties Private Limited, and high-end biologics CDMO operations from Stelis Biopharma Limited (renamed as OneSource). The integrated entity has already garnered substantial financial backing, with an equity commitment of Rs 8,010 million (approximately USD 95 million) from prominent investors.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.